A retrospective study led by Manisha Bahl at Massachusetts General Hospital evaluated the effectiveness of an FDA-cleared artificial intelligence (AI) algorithm in localizing interval breast cancers previously missed during digital breast tomosynthesis (DBT) screenings. The study, which examined 224 interval cancer cases from February 2011 to June 2023, found that the AI correctly identified one-third of these cancers, suggesting potential improvements in early detection. The research highlights significant differences in tumor characteristics between AI-detected and undetected cases.

Source: RSNA Radiology